Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study
Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study Source link
Osteoarthritis Candidate MM-II Showed Durable Pain Relief in Global Phase 2b Study Source link
Sun Pharma - Milmet Labs merger Source link
FY20 Q2 Financial Result - Transcript Source link
Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata ...
Sun Pharma completes acquisition of Concert Pharmaceuticals Source link
Sun Pharma Announces US FDA Approval for Generic Lenalidomide Capsules Source link
Sun Pharma to announce third quarter results on January 31, 2022 Source link
Sun Pharma launches CEQUA™ (cyclosporine ophthalmic solution 0.09% w/v), the first dry eye treatment with nanomicellar (NCELL™) technology*, in Canada ...
Q3 FY22 Financial Press Release Source link
Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the ...
Sun Pharma to introduce its version of Vortioxetine in India under an exclusive patent license from Lundbeck Source link
Sun Pharma Announces US FDA Approval for Generic Mesalamine Extended Release Capsules Source link
Sun Pharma to announce fourth quarter results on May 30, 2022 Source link
Sun Pharma to launch Brillo®, a first-in-class oral lipid-lowering drug in India Source link
Sun Pharma Acquires Uractiv™ Portfolio from Fiterman Pharma in Romania Source link
Sun Pharma to announce first quarter results on July 29, 2022 Source link
Sun Pharma and Cosmo Announce Territory Expansion of License and Supply Agreements for WINLEVI® to include Japan, Australia, New Zealand, ...
Sun Pharma acquires Disperzyme® and Phlogam® brands to strengthen its anti-inflammatory portfolio Source link
Sun Pharma Launches SEZABY™ (phenobarbital sodium) in the U.S. for Treatment of Neonatal Seizures Source link
Sun Pharma to Acquire Concert Pharmaceuticals Inc Source link
Sun Pharma to announce third quarter results on January 31, 2023 Source link
Sun Pharma launches Palbociclib, a novel targeted therapy for advanced breast cancer with a unique Patient Assistance Program Source link
Sun Pharma is Great Place To Work® Certified™ in India Source link
SEZABY™ (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures Source link
Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US Source link
“Apni Body Ki Suno” says the latest campaign of Sun Pharma’s Revital H Source link
Sun Pharma to announce second quarter results on November 01, 2022 Source link
Sun Pharma board to consider merger of export subsidiary Source link
EGM clears resolutions for split, buyback Source link
Sun Pharma H1 post results conference call on Wednesday October 22, 11am Source link
President to inaugurate Sun Pharma's research center Source link
Sun Pharma closes Able Labs acquisition in the US Source link
Sun Pharma's lead molecule enters Phase II in the US Source link
Sun Pharma announces settlement of litigation over generic Exelon® Source link
Sun Pharmaceutical extends tender offer for Taro December 19, 2008 Source link
Generic Eloxatin® and Imitrex® approval: shares 180-day marketing drug exclusivity for generic Eloxatin® Source link
Sun Pharma announces USFDA tentative approval for generic Boniva® Source link
Sun Pharma announces USFDA approval for generic Ultram® ER tablets Source link
Successful acquisition of DUSA Pharmaceuticals, Inc.U.S.A.by our subsidiary Source link
Sun Pharma announces US FDA approval for generic Cymbalta® Source link
CCI approves Ranbaxy acquisition by Sun Pharma Source link
Sun Pharma receives Warning Letter for Halol facility Source link
Sun Pharma & Moebius Medical sign deal to develop novel liposomal non-opiod pain product for osteoarthritis Source link
Sun Pharma Announces US FDA Acceptance of NDA for OTX-101 Source link
Investor Update Call Transcript Source link
FY21 Q2 Financial Press Release Source link
Sun Pharma receives DCGI approval for Molxvir® (Molnupiravir) in India Source link
ADANI Adani Enterprises Adani Group Aditya Birla Group Airtel Ambuja Cement Apollo Hospitals Apple Inc Aster DM Healthcare Bajaj Auto Bank of America Cigna Corporation Cognizant India Dabur India Dalmia Bharat Exxon Mobil FedEx Corp General Electric Godrej Group HAL Home Depot ICICI Bank Indian Bank Infosys JPMorgan Chase & Co Kubota Corporation L&T Mahindra & Mahindra Meta Platforms Microsoft National Aluminium Company Nestle India Royal Dutch Shell Samsung Global Saudi Aramco Standard Chartered Bank Steel Authority of India Sun Pharma Tata Consumer Products Tata Motors Tata Power Tata Steel UltraTech Limited Verizon Communications Voltas Limited
© 2022 incPres.com